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Abstract
Bacterial resistance to antibiotic treatment is a huge concern: introduction of any new
antibiotic is shortly followed by the emergence of resistant bacterial isolates in the clinic.
This issue is compounded by a severe lack of new antibiotics reaching the market. The
significant rise in clinical resistance to antibiotics is especially problematic in nosoco-
mial infections, where already vulnerable patients may fail to respond to treatment,
causing even greater health concern. A recent focus has been on the development of
anti-virulence drugs as a second line of defence in the treatment of antibiotic-resistant
infections. This treatment, which weakens bacteria by reducing their virulence rather
than killing them, should allow infections to be cleared through the body’s natural de-
fence mechanisms. In this way there should be little to no selective pressure exerted
on the organism and, as such, a predominantly resistant population would be unlikely
to emerge. However, much controversy surrounds this approach with many believing
it would not be powerful enough to clear existing infections, restricting its potential
application to prophylaxis. We have developed a mathematical model that provides
a theoretical framework to reveal the circumstances under which anti-virulence drugs
may or may not be successful. We demonstrate that by harnessing and combining the
advantages of antibiotics with those provided by anti-virulence drugs, given infection-
specific parameters, it is possible to identify treatment strategies that would efficiently
clear bacterial infections, while preventing the emergence of resistant subpopulations.
Our findings strongly support the continuation of research into anti-virulence drugs and
demonstrate that their applicability may reach beyond infection prevention.
Keywords: Antibiotic resistance, Anti-virulence drugs, Mathematical Modelling
1 Introduction
Bacterial resistance to antibiotic agents is an increasing problem in modern society. The
introduction of every new class of antibiotic, from the original β-lactam, penicillin, to the
more recent lipopeptides such as daptomycin, has been followed by the emergence of new
strains of bacteria resistant to that class, many emerging in the clinic only a few years after
the introduction of the drug [1, 2, 3]. Given that the pace of antibiotic discovery has dramat-
ically slowed down (most classes of antibiotic were discovered in the 1940s to the 1960s, the
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‘Golden Era’ of antibiotics, with the past forty years giving us only five significant new classes
[1, 3] and pharmaceutical companies devoting less research into discovering new antibiotics
[4, 5]), this poses a huge problem. Thus, development of novel treatments for bacterial infec-
tions is of utmost importance.
Traditional antibiotics are either classed as bacteriocidal or bacteriostatic, working to either
kill bacteria or inhibit bacterial growth respectively [2, 4]. While effective in eliminating sus-
ceptible bacterial infections, antimicrobials impose selective pressure on the bacteria, lead-
ing to the rise of resistant clones within the bacterial population. Resistance can be acquired
either through spontaneous chromosomal mutation and then selection by antibiotic use,
known as vertical evolution, or through acquiring genetic material from other resistant or-
ganisms, known as horizontal evolution [6]. Horizontal evolution occurs via mechanisms
such as conjugation, transformation and transduction [7] and can take place between strains
of the same or different bacterial species. Horizontal resistance can lead to multidrug resis-
tance and is a major concern in hospitals, where resistant bacteria are able to remain viable
despite antibiotic use, and are the cause of many serious nosocomial infections in already
vulnerable patients [7, 6].
It has been suggested that the focus of new drug development should be on targeting vir-
ulence, the bacteria’s ability to cause disease [2], but this approach remains controversial.
Anti-virulence drugs would minimize any harm caused by bacteria while they remain in the
host until they can be cleared by natural defences. This can occur either by being flushed
out of the system or by being eradicated by the host’s immune response. This should exert
little to no selective pressure on the bacteria but this has not yet been proved in vivo. Anti-
virulence drugs could target a range of mechanisms, including bacterial adhesion to host
cells, toxin delivery or virulence gene regulation, all necessary for successful infection [2, 4].
We adopt a modelling approach to investigate the viability of anti-virulence drugs in silico.
Our results suggest that, in combination with antibiotics and under specific treatment strate-
gies, anti-virulence drugs can be effective in treating bacterial infections where antibiotic
resistance is a concern. Optimal treatment strategies are likely to be specific to the patient,
infection and bacterial strain and (rather than attempt to pin-point exact strategies) we use
this theoretical framework as a ‘‘proof of concept’’, exploiting parameter surveys to investi-
gate a range of scenarios, highlighting the potential (and possibly the need) for addressing in-
fections with tailored treatments in the future. Given that every patient, infection and strain
of bacteria are different, it is impossible to obtain a conclusive set of parameters which will
suit all situations. We therefore exploit parameter surveys to ascertain under what conditions
certain behaviour will occur.
2 Model formulation
There are two main approaches usually taken when modelling the emergence of antibiotic
resistant bacteria: within-host models, or within-hospital compartmental models. Models
of hospital resistance usually follow a similar form to the classic ‘‘Susceptible-Infectious-
Resistant’’ (SIR) models of epidemiology, looking specifically at how nosocomial infections
will spread throughout the hospital, for example [8, 9, 10]. While such models are useful to
develop strategies to prevent the spread of resistance, our focus is on treatment strategies to
eliminate the emergence of a resistant subpopulation that has either arisen through random
mutation and clonal expansion or through cross-contamination within a particular infection
and under a specific treatment regimen. If the resistant bacteria within a single host can be
eliminated then the spread of resistance throughout the hospital is a less pressing concern.
Existing mathematical models that focus on the within-host emergence of resistance exam-
ine how antibiotic treatment strategies can both cause and be adapted to prevent the emer-
gence of antibiotic resistance, for example [11, 12]. Such models often neglect the effect of
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the host immune response, assuming it to be negligible or constant under the effect of the
antibiotic. Since the efficacy of anti-virulence drugs will depend at least in part on the host’s
innate immunity, we include cell-mediated innate immune response in the model.
The system consists of five interacting components: populations of antibiotic-susceptible
bacteria (S), antibiotic-resistant bacteria (R) and immune cells e.g. phagocytes (P), and con-
centrations of antibiotic (A) and anti-virulence drug (A∗). These interact as demonstrated in
Figure 1 and represent a generalised model of a local bacterial infection, such as a urinary
tract or wound infection.
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Figure 1: Schematic representation of the main interactions involved in an infection treated
by antibiotics and anti-virulence drugs with S (antibiotic-susceptible bacteria), R (antibiotic-
resistant bacteria), P (immune cells, e.g. phagocytes), A (antibiotic concentration) and A∗
(anti-virulence drug concentration). Both the phagocytes and antibiotic inhibit bacterial
growth, with the antibiotic having a greater effect on the susceptible bacteria than the re-
sistant ones, assuming only partial resistance. The anti-virulence drug increases the effec-
tiveness of the immune response in order to eliminate the bacteria more naturally, working
on both susceptible and resistant bacteria in the same way.
The growth of bacteria within a host is likely to saturate over time, as a result of space and
nutrient limitations. We therefore use a logistic growth term with baseline growth rate ηi , (i =
S,R) and a combined carrying capacity K , rather than simple exponential growth, to represent
the bacterial dynamics. We assume natural death of the bacterial cells is negligible relative
to the effects of the drugs and the immune system, but we do include a removal rate, ψ,
representing the body’s endogenous, physical clearance mechanisms (this can be expected
to vary depending upon infection type).
Due to the potential for multidrug resistance [6], the primary cause for concern in hospitals
is resistance due to horizontal evolution: acquiring new genetic material from other resistant
organisms. Horizontal evolution involves the transfer of the resistance gene, normally found
in sections of DNA known as transposons, from one plasmid to another. This takes place via
one of three main mechanisms: conjugation, transformation or transduction [6, 7]. We focus
on the most common of the three transmission mechanisms [7], conjugation, whereby one
bacterium transfers plasmid containing the genes for resistance to an adjacent bacterium
[6]. Research suggests that these plasmid-bearing, and thus antibiotic-resistant, bacteria
are subject to a fitness cost, c , lowering their growth rate [8, 9, 13, 14, 15], hence we choose
ηR = (1−c)ηS where 0< c < 1. Since this plasmid transfer occurs between adjacent bacteria,
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and we assume a well mixed population, we represent this interaction through mass action
kinetics with a conjugation rate, λ, proportional to the levels of both antibiotic-susceptible
and -resistant bacteria in the population [10, 11, 13, 16]. It has also been observed that it is
possible to lose the plasmid carrying the resistance genes [10, 16] and so this too is incorpo-
rated into the model via a constant reversion rate, ρ.
We assume that bacteria are consumed by phagocytes (immune cells) at rate γ. Rather than
assuming a constant phagocyte level, as is often done, we incorporate a more realistic rep-
resentation of cell-based, innate immune response into the model. Using a logistic style
term, phagocytes are recruited to the site of infection at a rate proportional to the amount of
bacteria present subject to an infection-site-specific, phagocytic carrying capacity, Pmax [17].
Phagocytes are lost through pathogen-induced apoptosis (at rate δ) and natural clearance
(at rate δP ) [18].
Antibiotic is either administered in one dose or assumed to be present at constant level (e.g.
intravenous delivery) and rapidly absorbed to the site of infection [8]. Elimination of the an-
tibiotic from the system, due to both degradation of the drug and clearance due to natural
flow through the body, is assumed to be independent of the bacterial population and follows
first order kinetics [8, 16]. The effect of the antibiotic on each bacteria type is modelled using
an Emax saturating response,
E imax A
A50
i+A
, subject to a maximum killing rate E imax and the antibi-
otic concentration required for half maximum effect, Ai50, for i = S, R ,[8, 12, 19, 20]. Note
that resistant bacteria are in reality often only partially resistant, thus in general we assume
E Rmax 6= 0 but E
R
max < E
S
max [12].
We assume the anti-virulence drug increases the effectiveness of the host’s immune response
by weakening the bacteria’s ability to counteract the host’s immune mechanisms. For exam-
ple, many bacterial pathogens use type III secreted effector proteins to reprogram cellular
pathways including those associated with host defence [21, 22]. In order to model this math-
ematically we base the effect of the anti-virulence drug on a saturating response, or Hill equa-
tion [23, 24], with γmax representing the maximum increased effect of the immune response
and γ50, the anti-virulence drug concentration for half maximum effect. We assume that
the anti-virulence drug has the same effect on both the antibiotic-resistant and susceptible
bacteria.
Combining the above, we obtain the following model of bacterial population dynamics dur-
ing antibiotic treatment:
d A
dt
= − αA, (2.1)
d A∗
dt
= − κA∗, (2.2)
dP
dt
= β
(
S+R
)(
1−
P
Pmax
)
− δ(S+R)P − δP P, (2.3)
dS
dt
= ηSS
(
1−
S+R
K
)
− µS(A)S −
(
γ+ζ
(
A∗
))
PS − λSR + ρR − ψS,
(2.4)
dR
dt
= (1−c)ηS R
(
1−
S+R
K
)
− µR (A)R −
(
γ+ζ
(
A∗
))
PR + λSR − ρR − ψR .
(2.5)
Here µi (A) =
E imax A
Ai50+ A
is the effect of the antibiotic on susceptible and resistant bacteria, re-
spectively, for i = S, R , and ζ
(
A∗
)
=
γmax A
∗
γ50+ A∗
is the effect of the anti-virulence drug. Default
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parameter values and definitions are as given in Table 1, but a range of parameter values are
explored throughout. Unless otherwise specified, we use the initial conditions:
A(0)= 4 µg/ml, A∗(0)= 4 µg/ml, P(0)= 0 cells, S(0)= 6000 cells, R(0)= 20 cells,
(2.6)
representing clinically realistic dosages (for instance 4 µg/ml is a value for meropenem in
Pseudomonas aeruginosa infections [25]) and the antibiotic-resistant subpopulation being in
the minority and introduced via cross-contamination. We note that the initial conditions for
numbers of bacteria are in line with the two studies from which we have principally sourced
our parameter values - see Table 1 and [17, 26]; given that we are intending to provide a
framework for future development of infection-specific treatment strategies and not positing
exact strategies here, this is sufficient for our purposes. The equations are solved numerically
in Matlab using the solver ode15s. We consider three scenarios in our numerical solutions:
an infection is treated by antibiotics alone, by an anti-virulence drug alone or by both drugs
in combination. In each case we wish to see how effective the treatment strategies are in
lowering bacterial load but crucially also in tackling the emergence of antibiotic-resistant
bacteria during the infection.
Table 1: Parameter notation with descriptions, estimated values and units. Immune-related
parameter values are taken from [17] and bacteria and antibiotic ones from [26]. Where no
source is given estimates have been made from what we believe to be realistic parameter
ranges, in keeping with the other parameters. In particular β is chosen so that the immune
system alone cannot clear the infection, the anti-virulence drug is assumed to have equiva-
lent efficiency to the antibiotic, and λ and ρ are chosen so that an antibiotic-resistant strain
can emerge to become dominant during infection. While we do not claim that these parame-
ters represent one particular infection-type, they should fall within a realistic range, enabling
us to investigate a spread of scenarios through variations to these values in the parameter
surveys provided throughout the study.
Parameter Description Units Estimated Value Source
α Elimination rate of antibiotic under distinct doses days−1 3.6 [26]
Elimination rate of antibiotic under intravenous therapy days−1 0 -
κ Elimination rate of anti-virulence drug days−1 3.6 -
Elimination rate of anti-virulence drug under intravenous therapy days−1 0 -
β Recruitment rate of phagocytes days−1 3 -
c Fitness cost of resistance dimensionless 0.1 -
δP Clearance rate of phagocytes days
−1 1.512 [17]
δ Bacterial induced death of phagocytes cells−1days−1 6×10−6 [17]
AS50 Antibiotic concentration for half maximum effect on susceptible bacteria µg/ml 0.25 [26]
AR50 Antibiotic concentration for half maximum effect on resistant bacteria µg/ml 5 [26]
ESmax Maximum killing rate of susceptible bacteria days
−1 36 [26]
ERmax Maximum killing rate of resistant bacteria days
−1 26.4 [26]
γ50 Anti-virulence drug concentration for half maximum effect µg/ml 5 -
γmax Maximum increased effectiveness of immune response cells
−1 days−1 0.035 -
h Hill coefficient dimensionless 1 -
K Carrying capacity of bacteria cells 109 [26]
ηS Growth rate of susceptible bacteria days
−1 24 [26]
Pmax Maximum number of phagocytes cells 1.8×10
5 [17]
γ Bacterial clearance by phagocytes cells−1days−1 2.4×10−4 [17]
λ Conjugation rate constant days−1 10−4 -
ρ Reversion rate constant days−1 10−6 -
ψ Removal rate days−1 0.7 -
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Figure 2: Numerical solutions to (2.1)-(2.5) with (a) no treatment (A(0) = A∗(0) = 0), (b) one
dose of antibiotic (A(0)= 4, A∗(0)= 0), (c) repeated dosing of antibiotic (A(τ)= 4 for τ= 0.5p ,
p ∈ 0,1,2, ... and A∗(0)= 0) and (d) constant antibiotic level (A(0) = 4, A∗(0) = 0,α= 0). With
no treatment, our parameter choice reflects the situation where the immune system cannot
clear the infection and a dominant population of antibiotic-resistant bacteria emerge. With
treatment, susceptible bacteria can be cleared but some antibiotic-resistant bacteria persist.
Note that here and in subsequent figures, we have adjusted the y-axes to enable visualisation
of any variables tending to zero.
3 Results
Antibiotic treatment (A(0)= 4 µg/ml, A∗(0)= 0 µg/ml)
We consider a scenario where the bacterial population at the site of infection is composed
predominantly of an antibiotic-susceptible subpopulation and a minor, resistant subpopu-
lation which has arisen through cross-contamination of the site with a resistant population
introduced from an environmental source (as is often the case during hospital-outbreaks)
[27, 28].
Firstly, we establish that our parameter set predicts the emergence of antibiotic-resistant bac-
teria in an infection when initially they exist in far smaller numbers than susceptible bacteria
(Figure 2a) but ultimately dominate the infection as a result of conjugation. The parame-
ter choice also reflects an infection that the immune system alone cannot clear (hence the
need for treatment). Due to acquisition of resistance via horizontal evolution from plasmid
transfer the resistant bacteria become dominant even without the selective pressure of an
antibiotic.
Antibiotics can either be administered in doses (α 6= 0) or continuously (α = 0). Our model
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Figure 3: Steady-state values of antibiotic-resistant bacteria for varying (a) A(0), (b) AR50 and
E Rmax (the last two simultaneously). In (a) we plot also the numbers of antibiotic-susceptible
bacteria to illustrate that they are cleared from the infection. Antibiotic-resistant bacteria
will only be cleared by antibiotics (in combination with the immune system) if resistance is
especially low (AR50 → 0 and E
R
max→∞).
predicts that under antibiotic dosing all susceptible bacteria may be eradicated from the in-
fection, however, as the antibiotic degrades out of the system the population of resistant
bacteria increases exponentially (Figure 2b and 2c). Upon a new dose of antibiotics being ad-
ministered, the level of resistant bacteria drops slightly (due to the allowance of only partial
resistance), subsequently quickly rising when the antibiotic degrades out of the system. Next,
we consider constant antibiotic administration (e.g. via intravenous therapy, Figure 2d). Sus-
ceptible bacteria are eliminated and the resistant bacteria reach a lower (but still high) steady
state than in the absence of any drug. Thus the model reflects the type of infection in which
we are most interested: one which cannot be cleared by either the immune system or antibi-
otics and in which antibiotic-resistance is a primary concern. For the remainder of this study
we consider only constant antibiotic concentration for mathematical simplicity.
Antibiotic treatment: parameter analysis
Evidently, the amount of antibiotic administered will have a large effect on the final rela-
tive population levels of antibiotic-susceptible and -resistant bacteria (Figure 3a). Though
some resistant bacteria persist regardless of the dosage, as a result of the default parameter
set representing only partial resistance, the bacterial load can be lowered by increasing the
quantity of antibiotic administered (though A0 must remain in a clinically realistic range).
Partial resistance is governed by the two parameters E Rmax and A
R
50 (the antibiotic’s maximum
killing rate for resistant bacteria and the antibiotic concentration for half the maximum effect
on resistant bacteria, respectively). The limits E Rmax → 0 or A
R
50 →∞ yield complete resis-
tance, and in Figure 3b we see what happens when these parameters are varied in combi-
nation. The sensitivity of the bacteria to a specific antibiotic determines the bacterial load
that persists in an infection treated by antibiotics: reducing the resistance level lowers this
number.
Though the results in this section so far are in no way surprising, they illustrate the power
of adopting a modelling approach to predict the outcome of a particular infection: if the
infecting strain can be isolated and the relevant parameters can be determined, it is possible
to predict the number of bacteria remaining at an infection site and therefore identify an
optimal treatment strategy.
We recall that a fitness cost can be incurred as a consequence of the bacteria bearing the
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Figure 4: Steady-state values of S, R and P in response to varying (a) fitness cost, c , and (b)
reversion rate,ρ. Sufficiently high c results in both subpopulations dying out (the susceptible
bacteria as a result of the antibiotic and the resistant bacteria because the fitness cost renders
them no longer viable) while there exists a range of ρ where both subpopulations can persist
in the long-term in spite of treatment by antibiotic.
plasmid that confers antibiotic resistance. It has been shown that, depending on the plas-
mid in question, the fitness cost incurred can vary from 0.09 to 0.25 [29] (as a proportion of
the non-plasmid-bearing growth rate), and that, over time, this cost can reduce, sometimes
eventually disappearing altogether [30]. Thus, it is important to look at the effect of varying
the cost of resistance on the whole infection (Figure 4a).
We observe that, as expected, a decrease in fitness cost increases the levels of resistant bac-
teria, and thus the level of immune cells (which are recruited in response to the presence
of bacteria), at the infection site. As c → 0, the plasmid is no longer exerting any significant
metabolic cost on the bacteria and thus they are in a stronger position when faced with an-
tibiotic pressure. Similarly, as c increases, we see the bacteria unable to compete against this
antibiotic pressure and once c > 0.48 (for our default parameter set), the benefit of resistance
no longer outweighs the costs incurred and the antibiotic-resistant subpopulation dies out
in the long term.
We also find that variations to the reversion rate, ρ, the rate at which a plasmid-bearing bac-
teria loses its plasmid [10, 16] can cause significant changes in the dynamics of the system
(Figure 4b). There exists a range of ρ where populations of both antibiotic-resistant and -
susceptible bacteria are maintained in the population at steady state despite the presence
of antibiotic: though the antibiotic kills the susceptible bacteria the resistant bacteria rejuve-
nates the susceptible population via plasmid loss. However, a sufficiently fast rate of plasmid
loss results in both populations dying out: the resistant population all revert back to plasmid
free susceptible bacteria leaving no plasmid-bearing bacteria to rejuvenate the population
once the antibiotic has taken effect. In reality we expect this reversion rate to be very low so
the situation whereby only resistant bacteria remain in the population is most likely [31].
Anti-virulence drugs (A(0)= 0 µg/ml, A∗(0)= 4 µg/ml)
We consider how effective anti-virulence drugs alone can be in treating a bacterial infec-
tion without antibiotics. Under our default parameter set (Figure 5) the anti-virulence drug
eliminates the antibiotic-resistant bacteria (this subpopulation is weaker due to the fitness
cost imposed on them via the presence of the plasmid). However, as opposed to an infection
treated only by antibiotics where antibiotic-resistant bacteria persisted, the anti-virulence
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Figure 5: Numerical solution to (2.1)-(2.5) when the infection is treated only by anti-virulence
drugs (A(0) = 0, A∗(0) = 4) (a) with doses every 0.5 days (κ = 3.6) and (b) continuous treat-
ment (κ= 0). Though the antibiotic-resistant bacteria are quickly cleared from the infection,
a subpopulation of antibiotic-susceptible bacteria persist because they grow at a faster rate
than the antibiotic-resistant bacteria. The reduced number of immune cells present at the
infection site as a result of the treatment lowering the total bacterial load leaves the immune
response incapable of clearing these remaining bacteria. For the remainder of this study we
consider only constant anti-virulence drug for simplicity.
drug fails to eliminate all the antibiotic-susceptible bacteria. Encouragingly though, the
number of bacteria remaining in the system is much lower than the number remaining af-
ter antibiotic treatment.
Despite the anti-virulence drug making the bacteria more vulnerable to the immune system
there is still a limit to how effective the immune response can be and hence why some bacte-
ria remain at the infection site. In modelling recruitment of the immune cells to the infection
site, we imposed a recruitment rate, β, proportional to the number of bacteria present at the
infection site, and a carrying capacity, Pmax. As such, the presence of immune cells is lim-
ited by the presence of bacteria. Subsequently, as the drug starts to take effect the bacterial
population diminishes, shortly followed by a decline in phagocyte population. Since this
treatment is based on enabling the immune system to clear the infection, as the immune
cell levels decrease so does the efficacy of the drug; hence we see a possible reason for the
persisting population of susceptible bacteria.
Thus although anti-virulence drugs are capable of dealing with the presence of antibiotic-
resistant bacteria if they grow more slowly than antibiotic-susceptible bacteria, it may not
be an effective treatment for the infection as a whole. In the following parameter analysis
we consider whether anti-virulence drugs would ever be capable of clearing an infection or
whether they might be more suitable for infection prevention.
Anti-virulence drugs: parameter analysis
Since the fitness cost is something that varies between bacteria and resistance type, we
again consider variations to the parameter c . This parameter effectively controls a competi-
tion for dominance between the antibiotic-resistant and -susceptible bacteria. Indeed, look-
ing at Figure 6, we see striking behaviour in the regime 0 < c < 0.006. For 0 < c < 0.0031 the
anti-virulence drug eliminates the population of antibiotic-susceptible bacteria with a level
of antibiotic-resistant bacteria persisting in the system. With such a small resistance cost the
susceptible bacteria are the more vulnerable strain and thus, when in competition with the
antibiotic-resistant bacteria, the susceptible bacteria lose out and experience the full effect of
9
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Figure 6: Steady state values of S and R for varying values of the cost of resistance, c , with
A(0) = 0, A∗(0) = 4 and all other parameters as given in Table 1. We see how, at an approxi-
mate fitness cost of c = 0.0031, the system exhibits a switch in behaviour and the steady state
values for antibiotic-resistant and antibiotic-susceptible bacteria are reversed, owing to the
susceptible bacteria being the weaker strain when the fitness cost for bearing the plasmid is
sufficiently small.
the anti-virulence drug. However, when c > 0.0031, the cost of antibiotic-resistance does not
outweigh the benefits from plasmid transfer and the plasmid-bearing bacteria are the more
vulnerable strain and are hence eliminated. This highlights the importance of understanding
the specific bacteria in question when choosing a treatment strategy for an infection.
A crucial aspect of an anti-virulence drug is its dependence on the immune system to be suc-
cessful: it may not be able to fully clear an infection under our default parameter set (Figure
5). Both the natural removal rate, ψ, and the baseline immune response, γ, are not only very
difficult to estimate, they are also patient- and site- specific. Along with inherent individual
differences in patients, we also see variation within a single host depending on their current
health. Since the main cause of concern for antibiotic resistance is in nosocomial infections
[7] patients may well be ill, immunosupressed or debilitated before the onset of infection.
Figure 7 shows the effect of varying these host-specific parameters on the anti-virulence
treatment. There exist circumstances when anti-virulence drugs can be completely effective,
however these occur when both the baseline immune response and natural flow past the in-
fection site are very high. Thus it is possible that anti-virulence drugs may only be successful
in either treating or preventing infection in a healthy individual. To test infection prevention
in a model, a more sophisticated set of equations that capture a specific mechanism of ac-
tion by an anti-virulence drug, as opposed to our deliberately general conceptual model, is
required. This will be developed in future work.
In all cases examined here the strain of resistant bacteria are eliminated, due to their reduced
fitness making them more vulnerable to the treatment. Thus, for an existing infection requir-
ing treatment, given that only susceptible bacteria remain, we next examine the option of
combining treatment by anti-virulence drugs with conventional antibiotics.
Combination therapy: antibiotics and anti-virulence drugs (A(0) = 4µg/ml, A∗(0)= 4µg/ml)
Our results so far suggest that anti-virulence drugs would rid an infection site of antibiotic-
resistant but not antibiotic-susceptible bacteria, so it would be expected that the addition of
antibiotics to this treatment would fully clear the infection. However, somewhat surprisingly,
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Figure 7: Steady-state value of susceptible bacteria and phagocyte levels when (a) natural
clearance (ψ) and (b) baseline immune response (γ) are varied. The bacteria can be cleared
from the infection but only when these host-specific parameters are sufficiently strong.
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Figure 8: Simulation of combination therapy (A(0)= A∗(0)= 4,α= κ= 0) with (a) c = 0.1 and
(b) c = 0.27.The combined treatments are only successful if the fitness cost associated with
antibiotic resistance is sufficiently high.
Figure 8a indicates that this is not necessarily the case (even under the same parameter set):
though susceptible bacteria are cleared, a number of resistant bacteria persist if the fitness
cost associated with antibiotic resistance is sufficiently low. This may be due to the dynam-
ics of the immune cells: as the introduction of both drugs rapidly decreases the population
of susceptible bacteria we also see a decline in the number of immune cells. Due to the de-
pendence of the anti-virulence drug on the immune system, this decline may subsequently
stunt the effectiveness of the drug, allowing the antibiotic-resistant population to build up to
a level with which the immune system then cannot compete. In Figure 8b, however, we see
that raising the fitness cost to c = 0.27 can result in both subpopulations being eliminated
due to the additional weakness imposed on the antibiotic-resistant bacteria (we note that
this is just outside the possible range for c suggested in [29]).
Excitingly, imposing a time delay on the administration of one of the drugs can allow combi-
nation therapy to be successful regardless of the fitness cost: see Figure 9. When c = 0.1, the
infection can be fully cleared if the antibiotic is administered 0.02 days (i.e. roughly 30 min-
utes) after the anti-virulence drugs, though the bacterial load in this time delay will greatly
increase. Reversing the treatment order is also successful, see Figure 10. Here the delay is
longer (and hence clearing the infection takes longer) but the increase in bacterial load be-
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Figure 9: Results of administering an anti-virulence drug to the infection site, followed by an
antibiotic after (a) 0.01 days and (b) 0.02 days when c = 0.1. If the delay between drugs is suf-
ficient, the anti-virulence drug is able to eradicate the antibiotic-resistant bacteria, allowing
the antibiotic to deal with the remaining susceptible bacteria.
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Figure 10: Results of administering an antibiotic to the infection site, followed by an anti-
virulence drug after (a) 0.5 days and (b) 0.6 days with c = 0.1. The required delay between
drugs for clearance of the infection is longer if the drugs are administered in this order than
vice versa (compare with Figure 9).
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Figure 11: An infection consisting solely of (partially) antibiotic-resistant bacteria (S(0) =
0,R(0) = 6000) treated by both antibiotics and anti-virulence drugs simultaneously with (a)
c = 0.01 and (b) c = 0.02. The combination therapy is capable of clearing the infection, but
only if the fitness cost of antibiotic resistance is sufficiently high.
fore addition of the second drug is lower in this instance. Thus, we see that in combining two
treatments, one which is more effective towards resistant bacteria and one which favours
susceptible bacteria, we can effectively eliminate all bacteria, provided a time delay is incor-
porated to enable both drugs to have full effect.
So far, all our simulations have focused on an infection where the antibiotic-resistant popula-
tion are initially in the minority. In Figure 11 we consider the effect of this combination ther-
apy on an infection consisting entirely of antibiotic-resistant bacteria (S(0)= 0,R(0)= 6000).
Interestingly, though neither drug in isolation will clear the infection, the administration of
both drugs with no time delay between them can clear the infection provided c > 0.01 for our
default parameter set. Thus combining antibiotics and anti-virulence drugs can even be suc-
cessful in treating infections consisting solely of antibiotic-resistant bacteria (remembering
that we are considering the bacteria to be partially resistant to the antibiotics). In addition, if
we consider the scenario where antibiotic-resistance has occurred via spontaneous chromo-
somal mutation (hence λ = ρ = 0) and no fitness cost is therefore incurred (c = 0), delayed
combination therapy again works, this time with delays of 0.03 days if the anti-virulence drug
is administered first and 0.5 days if vice versa (data not shown), again underlining the need
to fully understand the infection-type to design the treatment strategy correctly.
4 Discussion
Bacterial resistance to antibiotics is an increasing problem in today’s society, more specifi-
cally in hospital settings where already vulnerable patients are exposed to strains of bacteria
upon which conventional antibiotics have no effect. It has been widely suggested that in
order to combat this emergence of resistance, research focus needs to shift from developing
new antibiotics to novel treatment strategies that target bacterial virulence: an anti-virulence
drug that promotes natural clearance through a weakening of their ability to counteract the
immune response. This has given rise to much discussion of the potential success of such
an approach: would these drugs be capable of clearing an infection or would they be better
suited to infection prevention? Since these drugs are still in the very early stages of develop-
ment, we have developed a mathematical model to test their potential efficacy in silico.
Our model suggests that, if used in isolation, an anti-virulence drug may not be capable of
clearing an infection as it relies too heavily on the host immune system which was not strong
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enough to clear the infection itself in the first place (hence the need for treatment). The
immune-related parameters are highly host-specific, though, and if taken to be representa-
tive of a healthy individual then the anti-virulence drug could well deal with an infection, sug-
gesting that the drug could be useful for prophylaxis. However, since antibiotic resistance is
mainly a problem in hospital settings, where patients are more vulnerable, this dependence
on the immune system is likely to be a limitation of the proposed treatment. Nevertheless, re-
gardless of not being able to completely clear the bacterial infection in such immunocompro-
mised patients, we do find some promising results. The persisting bacterial load is not only
at a much lower level than the model predicted after antibiotic treatment, but importantly
the antibiotic-resistant bacteria were eliminated (due to the fitness cost associated with resis-
tance) leaving only antibiotic-susceptible bacteria at the infection site. These results led us
to investigate the potential of combination therapy. Treatment by both anti-virulence drugs
and antibiotics could fully clear an infection if the fitness cost associated with antibiotic-
resistance was sufficiently high. If this cost was lower, combination therapy could still be
successful through the imposition of a time delay between treatment types, but the success
of this approach was sensitive to the choice of delay between the drug types.
While underpinning the potential of anti-virulence drugs in a theoretical framework, this
study also highlights the need to better understand patient- and site-specific parameters
pertinent to an infection before optimal treatment strategies can be predicted. Mathemat-
ical modelling is an extremely useful tool for predicting such things, but the results will be
dependent on specific parameters within an infection, for example the level of resistance the
infecting strain displays to a particular antibiotic, the likely bacterial load at an infection site
or the time taken for treatment to reach the infection site. Thus, further work remains to
parameterise the model to given pathogens, infection sites and patients. Furthermore, the
model can be extended to be anti-virulence drug-specific. For example, anti-adhesive drugs
that prevent bacteria binding to host cells should increase the natural clearance rate, rather
than promoting the innate immune response, and this can be accounted for in extensions to
the model. Such efforts will greatly enhance the predictive powers of this type of model and
contribute to the future design of effective treatment regimen for bacterial infections.
5 Summary
Antibiotic resistance in bacteria has long been recognised as a problem for effective treat-
ment of infections, yet it is only more recently that the urgent need for antibiotic alternatives
has become widely accepted. We have presented here a model of a generalised treatment
strategy for changing the target of the drug to promote natural clearance. Our results sup-
port the continuation of research into anti-virulence drugs both in the context of treating
infections and in aiding with the elimination of the spread of antibiotic-resistant bacteria
from an infection and through hospital settings.
Throughout our analysis of these models we have highlighted some important issues that
need to be considered when designing treatment strategies such as the importance of tailor-
ing treatment to specific conditions of the host and how the success of combination therapy
(use of more than one drug type) depends highly on the dosing schedule. Most importantly,
however, we have shown conditions under which treatment strategies will be successful and
hence, provided a proof of concept for the potential such treatments should have to elimi-
nate the problem of antibiotic resistance.
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